Market cap
$2.3b
End-of-day close multiplied by current shares on issue.
A tax line that flipped from +30.2% to -46.0% drove the NPAT divergence while pre-lease free cash flow stayed below the historical range at -$52.5m.
Revenue context before the current result.
Operating cash flow across covered periods.
Operating working-capital absorption or release by reporting period.
Statutory profit after tax across covered periods.
Market context
A close-dated read on what the market price implies next to the latest verified filing inputs. Unavailable metrics stay visible when the absence is useful context.
The latest close and share count context for the market price.
Market cap
$2.3b
End-of-day close multiplied by current shares on issue.
How the market price compares with recent earnings and cash-flow inputs.
P/E
Not available
Not meaningful when recent earnings are negative.
EPS
-0.17
Recent filing-derived earnings per share.
PEG
Not available
Not available for this company right now.
EV/EBITDA
44.25x
Enterprise value compared with recent EBITDA.
P/FCF
12.41x
Market cap compared with recent free cash flow.
P/B
0.57x
Market value compared with latest reported equity.
Yield and fund-style valuation where the company shape supports it.
Dividend yield
0.0%
Trailing dividends compared with the latest close.
Total return
Not available
Available once dividend and adjustment data are verified.
Key metrics
HY25 vs HY24
Revenue
$366.3m
+13.4% ↑ vs $323m
EBITDA
—
— vs $146.3m
Net profit after tax
$94.4m
-49.4% ↓ vs $186.7m
Net cash inflow from operating activities
$282.8m
-16.3% ↓ vs $337.9m
Declared dividend per share
0.0c
flat vs 0.0c
Profit before tax
$174.8m
+21.9% ↑ vs $143.4m
Cash and cash equivalents
$22.6m
-32.2% ↓ vs $33.3m
Total assets
$12.8b
-2.1% ↓ vs $13.1b
What changed
NPAT fell 49.4% to $94.4m as the effective tax rate flipped from +30.2% to -46.0%, opening a 71.3pp gap between PBT and NPAT growth. Revenue grew 13.4% to $366.3m, within the historical range (mean 13.8%). Pre-lease free cash flow improved to -$52.5m from -$158.4m but remained below the historical baseline (mean +$104.9m, range +$51.8m to +$206.7m). Operating cash flow fell 16.3% to $282.8m while capex rose 138.8% to $313.3m, taking capex intensity to 85.6% of revenue. Total equity declined 11.6% to $4.3b, gross borrowings rose 3.2% to $2.6b, and ROE compressed to 2.2% from 3.8%. No interim dividend was declared.
What matters
PBT growth of 21.9% is the cleaner operating read; the 49.4% NPAT decline reflects the tax flip, not operating deterioration. The release also discloses an "IFRS profit before tax and fair-value movements" (PBTF) of -$79.8m versus -$17.8m prior, which suggests the underlying result excluding fair-value gains actually worsened. The reported PBT improvement therefore relies materially on fair-value movements rather than trading performance.
Cash quality is weak in absolute terms. Pre-lease FCF of -$52.5m is below Annolyse's historical range (mean +$104.9m). OCF fell 16.3% while capex more than doubled to consume 85.6% of revenue. The headline improvement against the -$158.4m prior comparable is real, but the absolute level signals that development spending is outpacing internal cash generation by a wider margin than recent baseline periods.
The balance sheet is absorbing the gap. Equity fell 11.6% to $4.3b as gross borrowings rose to $2.6b. ROE almost halved to 2.2% from 3.8%. With dividends held at zero, capital is being directed to the development pipeline at the expense of shareholder return metrics, which matters because rising leverage and falling returns together compress headroom for any further fair-value impairments.
Expectations
Annolyse's second-half shape data shows HY24 represented 46.8% of FY24 revenue, indicating modest second-half topline weighting. NPAT seasonality is unreliable: HY24 contributed 3,909% of FY24 NPAT because H2 FY24 was deeply loss-making, so the prior shape is not a usable run-rate. Annualised current revenue of $732.5m would imply mid-single-digit full-year revenue growth from the FY24 base of $689.9m. The release does not support a firm view on full-year NPAT given the dependency on fair-value movements and the step-up in capex commitment.
Quality of result
The PBT growth above the historical baseline range is genuine, but the disclosed PBTF deterioration (-$79.8m versus -$17.8m) indicates fair-value movements are doing meaningful work in the headline. The effective tax rate sits below Annolyse's historical range, making NPAT a poor proxy for operating progress this period.
Cash quality is the clearer concern. With OCF down 16.3% and capex up 138.8%, pre-lease FCF of -$52.5m sits below the historical range despite improving on prior comparable. The receivable days movement to 10.6 days is at the lower edge of historical range, so the debtor side is benign, but operating working capital still absorbed $14.8m and inventory days fell to 0.9 from 4.7. With zero dividend and equity declining 11.6%, the development pipeline is being funded by drawing on the balance sheet rather than internal cash flow, which limits durability if fair-value tailwinds reverse.
Unresolved
This briefing cannot assess the underlying property-level fair-value assumptions or the project-level economics driving the development capex step-up.
Chat
Ask follow-up questions about Ryman Healthcare's HY25 result.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Open to load segment breakdown.
Open to load analytical metrics.
Open to load key metrics.
Ryman Healthcare Limited - Announcement Numbers - 30 September 2024
HY25 / results announcementRyman Healthcare Limited - Consolidated Interim Financial Statements - 30 September 2024
HY25 / financial reportRyman Healthcare Limited - Media Release - 30 September 2024
HY25 / media releaseRyman Healthcare Limited - Results Presentation - 30 September 2024
HY25 / results presentationRyman Healthcare Limited - Announcement Numbers and Financial Statements - 30 September 2023
HY24 / financial reportRyman Healthcare Limited - Media Release and Key Statistics - 30 September 2023
HY24 / media releaseFY24 Result Press Release_FINAL
FY24 / results announcementFY24 Result Press Release_FINAL
FY24 / results releaseRyman Healthcare Limited – Financial Statements – 31 March 2024 (including Deloitte Audit Report)
FY24 / financial reportRyman Healthcare Limited - 1H25 Results Webcast Replay
HY25 / commentaryRelated insights
Cross-company views selected from the metrics in this briefing.
Earnings quality and statutory distortions
PBT and NPAT growth diverged by 71.3pp, with a distortion flag in the result.
Dividend coverage and payout pressure
Dividend payout versus NPAT is 0.0%.
Revenue growth context
Revenue growth was 13.4% for this reporting period.
ROE and capital efficiency
ROE was 2.2%, -1.6pp versus the prior comparable period.
Get the next Ryman Healthcare briefing and related NZX reporting-season updates by email.